Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas

Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas

Abstract Patients with advanced gastric and colorectal cancers have limited treatment options. Since mesothelin is highly expressed in these tumour types, we evaluated the therapeutic benefits of anti‐mesothelin hYP218 CAR T cells alone, and in combination with anti‐PD1 antibody, pembrolizumab. GEPI...

Full description

Saved in:
Bibliographic Details
Main Authors: Sameer Mir, Abhilash Venugopalan, Jingli Zhang, Nishanth Ulhas Nair, Manjistha Sengupta, Manakamana Khanal, Chaido Stathopoulou, Qun Jiang, Raffit Hassan
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Clinical and Translational Medicine
Subjects:
anti‐PD1
CAR T cell
colorectal cancer
gastric cancer
mesothelin
pembrolizumab
Online Access:https://doi.org/10.1002/ctm2.70057
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items